Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets

AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Published
13 Feb 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
SEK 228.00
26.8% undervalued intrinsic discount
08 Aug
SEK 167.00
Loading
1Y
-31.6%
7D
-4.4%

Author's Valuation

SEK 228.0

26.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.60%

Shared on23 Apr 25
Fair value Decreased 1.07%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 3.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 1.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.